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Glutamate (Glu), gamma amino-butyric acid (GABA), 
and excitatory/inhibitory (E/I) imbalance have inconsist-
ently been implicated in the etiology of schizophrenia. 
Elevated Glu levels in language regions have been sug-
gested to mediate auditory verbal hallucinations (AVH), 
the same regions previously associated with neuronal 
hyperactivity during AVHs. It is, however, not known 
whether alterations in Glu levels are accompanied by 
corresponding GABA alterations, nor is it known if Glu 
levels are affected in brain regions with known neuronal 
hypo-activity. Using magnetic resonance spectroscopy 
(MRS), we measured Glx (Glu+glutamine) and GABA+ 
levels in the anterior cingulate cortex (ACC), left and 
right superior temporal gyrus (STG), and left inferior 
frontal gyrus (IFG), in a sample of 77 schizophrenia 
patients and 77 healthy controls. Two MRS-protocols 
were used. Results showed a marginally significant pos-
itive correlation in the left STG between Glx and AVHs, 
whereas a significant negative correlation was found in the 
ACC. In addition, high-hallucinating patients as a group 
showed decreased ACC and increased left STG Glx levels 
compared to low-hallucinating patients, with the healthy 
controls in between the 2 hallucinating groups. No signif-
icant differences were found for GABA+ levels. It is dis-
cussed that reduced ACC Glx levels reflect an inability of 
AVH patients to cognitively inhibit their “voices” through 
neuronal hypo-activity, which in turn originates from in-
creased left STG Glu levels and neuronal hyperactivity. 
A  revised E/I-imbalance model is proposed where Glu-
Glu imbalance between brain regions is emphasized rather 
than Glu-GABA imbalance within regions, for the under-
standing of the underlying neurochemistry of AVHs.
Key words:  Magnetic resonance imaging (MRI)/MR 
spectroscopy (MRS)/schizophrenia/hallucinations/
auditory verbal hallucinations/glutamate/GABA/Glx/
excitatory/inhibitory (E/I) imbalance model
Introduction
Auditory verbal hallucinations (AVHs) is a key symptom 
in schizophrenia, and refers to auditory experiences of 
“hearing a voice,” in the absence of an external auditory 
source.1,2 Neuronal underpinnings of AVHs are to date 
not fully understood, although imbalance between excita-
tory and inhibitory influences (E/I imbalance) in the brain 
have been proposed as potential mechanisms (ref.3 for a 
review), and appear to exist on multiple levels including 
large-scale cognitive networks (between regions) and 
small-scale neuronal circuits (within regions). For large-
scale cognitive networks, evidence suggests E/I imbalance 
between language and cognitive control regions in schiz-
ophrenia patients. fMRI meta-analyses have suggested 
(hyper-)activation during AVHs in a bilateral fronto-
temporal network including speech perception (superior 
temporal gyrus [STG]4) and speech production (Broca’s 
area in inferior frontal gyurs [IFG]) areas.1,5 Furthermore, 
a consistent finding in schizophrenia patients is hypo-
activity in prefrontal cortex (eg, anterior cingulate cortex, 
ACC).6 These findings go along with findings of impaired 
cognitive control/executive functions and regulation of 
attention in these patients.7–9 Based on findings from be-
havioral and neuroimaging studies, Hugdahl10 proposed 
a 2-fold model of the pathophysiology underlying AVHs 
involving neuronal hyper-excitation in temporal lobe 
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speech perception regions leading to the perception of a 
“voice” in a bottom-up way, and frontal lobe top-down 
failure in suppressing the bottom-up input (c.f.11,12). The 
aim of the present study was to investigate any under-
lying neurotransmitter excitatory-inhibitory correspond-
ence to the bottom-up and top-down imbalance found at 
the cognitive/behavioral level of explanation (cf.13).
Dysfunction of glutamatergic and/or gamma amino-
butyric acid (GABA)-ergic neurotransmitter systems is 
implicated in the etiology of schizophrenia, and could 
result in regional imbalances of excitation and inhibi-
tion. Dysfunction of glutamatergic transmission has 
been attributed to hypo-function of the N-methyl-D_as-
partate (NMDA)-type glutamate (Glu) receptor, and 
NMDA receptor dysfunction on GABAergic neurons 
could lead to disinhibition and increase of Glu release.14 
Administration of the NMDA antagonist ketamine to 
healthy volunteers has produced symptoms comparable 
to that of schizophrenia patients,15–17 and exacerbated 
psychotic symptoms (including auditory hallucinations) 
in schizophrenia patients.17,18 In support of deficits in 
GABAergic neurotransmission is the consistent post-
mortem finding of lowered expression of glutamatergic 
acid decarboxylase 67 (GAD67) mRNA (eg,19–21), which 
codes for a protein involved in the conversion of Glu to 
GABA (for a review see ref.22). In vivo studies of altered 
Glu and GABA levels are further needed in confirming a 
Glu-GABA imbalance hypothesis of schizophrenia.
Glu and GABA concentration levels can be measured 
in vivo by hydrogen magnetic resonance spectroscopy 
(1H-MRS). MRS takes advantage of the magnetic prop-
erties of the hydrogen proton. The surroundings of the 
hydrogen proton(s), ie, the molecule in which the proton 
is bound, affect its magnetic properties.23 As a result, it 
is possible to identify signals from different molecules. 
Multiple studies have investigated Glu and GABA con-
centrations in schizophrenia patients applying MRS, al-
though results are inconsistent. A  recent meta-analysis 
of Glu24 concluded of generally elevated Glu, glutamine 
(Gln), or of the composite signal, Glx, in sub-cortical re-
gions in schizophrenia patients. For the ACC, significantly 
elevated Glx levels were found only for a high-risk pop-
ulation. A  recent meta-analysis on GABA25 concluded 
with no overall difference between patients and controls 
in spite of single studies confirming low GABA levels in 
patients in the ACC.26,27 One reason for inconsistent re-
sults in MRS studies might be different symptom profiles 
in patients across samples.24
Only a few studies have investigated Glu in relation 
to auditory hallucinations. Elevated Glu levels have 
been found associated with auditory hallucination se-
verity in the left STG,28 and left IFG.28,29 Whether these 
hallucination-related Glu alterations are accompanied 
by GABAergic changes within the same regions—as pre-
dicted by the E/I imbalance model—has not yet been in-
vestigated. It should also be noted that both left STG1,4 
and left IFG1 have been related to neuronal hyperactivity 
during hallucinations in schizophrenia patients. Whether 
similar relationships exist between AVH and Glu in re-
gions related to hypo-activity is unknown. In fact, one 
might consider that there also exist Glu-Glu imbalances 
and/or GABA-GABA imbalances between regions asso-
ciated with respectively hyper- and hypo-activity, but this 
remains to be tested.
The current study, therefore, aimed to explore whether 
Glu-GABA imbalances are associated with severity of AVHs 
in schizophrenia patients in language (left and right STG, 
and left IFG) and executive (ACC) regions. The left and 
right STG and ACC regions were examined with Protocol 
1 (n = 39); and the left IFG and STG were examined with 
Protocol 2 (n = 38). The 2 MR protocols used did not differ 
with regard to the aims of the study. We hypothesized that 
relationships between AVH and Glu and GABA levels 
would be region-specific, such that positive Glu and negative 
GABA correlations with AVH would be seen in the STG and 
IFG regions, reflecting increased excitation (hyperactivity) in 
the language regions, while the reverse relationship should 
be found for the ACC region reflecting decreased excitation 
(hypo-activity) in executive/cognitive control regions.
Methods
Participants
Seventy-seven schizophrenia patients (mean age 29.83, 
SD 11.48) and 77 matched controls (mean age 30.23, SD 
10.23) underwent MRS scanning (some tested repeatedly 
at 2 different time points, see table 1 for sample details). 
The patients were recruited via the Bergen Psychosis 
Study 2. Two MRS data collection protocols, including 
different voxel placements, were used. One protocol (here-
after referred to as Protocol 1) included MRS recordings 
from the left STG, right STG, and ACC and was used for 
39 patients and 39 controls. The second protocol (here-
after referred to as Protocol 2) included MRS recordings 
from the left STG and left IFG and was used for 38 pa-
tients and 38 controls (see figure 1 for voxel placement). 
Data from the 2 protocols were pooled in the analyses.
The controls were individually matched to the patients 
with regard to sex and age (within ±3 y from their respec-
tive controls), except for 9 patients who were outside of 
the 3 years range (4–7 y). Patients and controls were in ad-
dition matched in terms of scanning protocol, and hand-
edness, with the exception of ambidextrous patients who 
were matched with right-handed controls. All patients that 
were on medication used second-generation antipsychotic 
medication while some, in addition, used first-generation 
antipsychotics (mean defined daily dose (DDD):1.03, SD 
0.62). A few patients also used anti-depressants (n = 10), 
mood stabilizers (n = 2), opioids (n = 1), benzodiazepines 
(n = 18), anticholinergic (n = 5), or ADHD medication 
(n = 1). All patients were diagnosed with schizophrenia 
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manual (World Health Organization, 1992; Norwegian 
translation; https://ehelse.no/standarder-kodeverk-og-
referansekatalog/helsefaglige-kodeverk/kodeverket-icd-
10-og-icd-11). Mean illness duration for the patient group 
was 4.34 years, SD 7.68. Global severity of symptoms in 
the patient group as assessed by the Positive and Negative 
Syndrome Scale (PANSS30) total score were 62.48, SD 
17.63 (Positive-total 15.53, SD 5.51; Negative-total 15.03, 
SD 5.02; General-total 31.91, SD 9.70). The study was ap-
proved by the Regional Committee for Medical Research 
Ethics at the University of Bergen (REK no 2010–3387), 
and conducted according to the Declaration of Helsinki. 
All participants received oral and written information 
about the study before signing a written consent form.
Hallucinations were assessed with the PANSS30 inter-
view. All PANSS-raters were trained and certified by the 
PANSS Institute, and satisfactory inter-rater reliability 
was documented. Severity of auditory hallucinations 
were scored from the P3 item on the PANSS positive 
sub-scale, ranging from 1 to 7 (1 = absent, 7 = extreme). 
Although the PANSS questionnaire does not explicitly 
distinguish between modalities, hallucinations in the au-
ditory domain (as “voice hearing”) is most common,31,32 
and the P3 item is hereafter referred to as AVH. The 
PANSS scores were obtained on the same day as the 
MRS measurements.
MR Image Acquisitions
Imaging data were acquired with a 3T GE-SignaHDx 
MRI scanner. See table 2 for MR acquisition parameters. 
Unsuppressed water reference spectra (8 repetitions) 
Table 1. Regional Concentration Means and SDs of Glx, Glutamate, Glutamine, GABA (Institutional Units), and Data Quality 
Parameters of the Patients and Controls That Were Included in Data Analysis
Patients Controls
N Mis/ Excl. Mean SD N Mis/ Excl. Mean SD
LSTG P Glx 92 (76) -/1 15.73 4.10 77 -/- 15.87 4.19
  Glutamate 81 (67)  13.23 2.13 60  13.61 2.0
  Glutamine 81 (67)  3.60 2.54 60  4.06 2.63
  SNR 92 (76)  39.55 12.17 77  40.81 12.28
  FWHM 92 (76)  0.07 0.02 77  0.07 0.02
 MP GABA 83 (68) 2/8 4.95 0.97 75 -/2 4.82 1.08
  SNR 83 (68)  21.51 5.94 75  20.53 6.36
  FWHM 83 (68)  0.07 0.02 75  0.07 0.02
LIFG P Glx 48 (37) 1/- 16.93 2.86 38 -/- 16.18 3.23
  Glutamate 46 (36)  14.28 1.88 34  14.35 1.8
  Glutamine 46 (36)  3.12 1.64 34  2.75 1.5
  SNR 48 (37)  42.48 9.02 38  47.29 6.79
  FWHM 48 (37)  0.06 0.01 38  0.05 0.01
 MP GABA 47 (37) 1/1 5.47 0.77 38 -/- 5.4 0.84
  SNR 47 (37)  27.68 3.93 38  28.45 4.16
  FWHM 47 (37)  0.06 0.02 38  0.06 0.02
ACC P Glx 43 (38) 1/- 20.18 3.33 37 -/2 19.83 3.59
  Glutamate 36 (33)  17.09 1.80 33  16.55 1.69
  Glutamine 36 (33)  4.22 2.39 33  4.31 2.28
  SNR 43 (38)  40.51 7.26 37  41.46 6.03
  FWHM 43 (38)  0.06 0.02 37  0.06 0.01
 MP GABA 42 (37) 1/1 4.44 0.83 38 -/1 4.59 0.82
  SNR 42 (37)  18.41 6.15 38  19.05 5.50
  FWHM 42 (37)  0.05 0.01 38  0.06 0.01
RSTG P Glx 42 (37) 2/- 22.30 3.25 38 -/1 21.14 4.31
  Glutamate 40 (35)  16.40 1.96 35  15.34 2.51
  Glutamine 40 (35)  6.95 3.49 35  7.08 3.66
  SNR 42 (37)  33.71 9.51 38  31.76 8.13
  FWHM 42 (37)  0.07 0.02 38  0.08 0.02
 MP GABA 37 (32) 2/5 4.63 1.13 37 -/2 4.43 1.28
  SNR 37 (32)  14.05 4.93 37  14.22 4.84
  FWHM 37 (32)  0.08 0.03 37  0.09 0.03
Note: LSTG, left superior temporal gyrus; LIFG, left inferior frontal gyrus; ACC, anterior cingulate cortex; RSTG, right superior tem-
poral gyrus; P, PRESS sequence; MP, MEGA-PRESS sequence; Mis, missing spectra; Excl, excluded spectra; SNR, signal-to-noise 
ratio; FWHM, full-width at half  maximum (linewidth). N refers to number of observations (as some patients were tested repeatedly at 2 
sessions), and in parentheses the number of unique subjects. Number of participants differ across regions and groups (patients and con-
trols) due to missing or excluded (low quality) spectra for single measurements. N also differ between Glx and glutamate/glutamine due 











were acquired automatically after the acquisition of 
water-suppressed metabolite spectra in both proto-
cols. A  scanner up-grade was conducted between data 
collection of Protocol 1 and 2, including a change of 
head-coil from 8 to 32 channels.
Data Analysis
MRS data from the PRESS sequence were analyzed using 
the LCModel version 6.3-1J,33 with the standard basis-set 
incorporating components from 15 metabolites (Alanine, 
Aspartate, Creatine, γ-amino-butyric acid, Glucose, Gln, 
Glu, Glycerophosphorylcholine, Phosphorylcholine, 
Lactate, myo-inositol, N-acetylaspartate, 
N-acetylaspartylglutamate, scyllo-inositol, and Taurine). 
Basic processing of MEGA-PRESS data was achieved 
using in-house scripts to perform coil combination, 
phase correction, alignment, and residual water subtrac-
tion before subtracting edit-OFF from edit-ON parts to 
yield the final difference spectrum for each acquisition. 
This spectrum was then quantified in LCModel with the 
mega-press-3 spectra type, using a simulated basis set34 
with Kaiser coupling constants.35 Metabolite estimates 
were scaled to an internal water reference, accounting for 
differing water concentration in the different tissue classes 
(GM, WM, CSF), partial volume effects, and metabolite 
relaxation times and differing water relaxation times be-
tween the tissue classes.36 Tissue content within the MRS 
voxel was estimated from the T1-image using the seg-
mentation tool of the Statistical Parametric Mapping 
(SPM8) software (www.fil.ion.ucl.ac.uk/spm). Individual 
spectra were subject to quality control, which led to the 
rejection of inadequate spectra (see table 1 for excluded 
spectra, and spectral quality parameters, and supplemen-
tary figure S1 for spectrum examples and information on 
quality control procedure). For further details on analysis 
procedure, see ref.37 Glx and GABA+ (GABA including 
macromolecules) levels were used in statistical analyses.
Statistical Analysis
Glx and GABA+ values were subjected to statistical anal-
ysis using Linear mixed models available in the SPSS 
software package (https://www.ibm.com/analytics/
Table 2. MR Acquisition Parameters for Protocol 1 and 2
N Regions Sequence TR TE TI FOV Rep Voxel size (m3)
Protocol 1 39 T1 Whole brain 3DSPGR 7.74 2.9 500 260  1 × 1 × 1
  MRS LSTG,RSTG, PRESS 1500 35   128 STG: 24 × 40 × 30
  ACC       ACC: 40 × 40 × 25
    MEGA-PRESS 1500 68   128  
Protocol 2 38 T1 Whole brain 3DSPGR 6.8 2.95 450 256  1 × 1 × 1
  MRS LSTG, LIFG PRESS 1500 35   192 LSTG: 24 × 30 × 31
    MEGA-PRESS 1500 35   192 LIFG:24 × 38 × 28
Note: LSTG, left superior temporal gyrus; LIFG, left inferior frontal gyrus; ACC, anterior cingulate cortex; RSTG, right superior tem-
poral gyrus; PRESS, point-resolved spectroscopy sequence; MEGA-PRESS, Mescher-Garwood PRESS; TR, repetition time; TE, echo 
time; TI, inversion time; FOV, field of view; Rep, repetitions. The repetitions for the MEGA-PRESS acquisition refer to the number of 
edit ON/OFF pairs acquired.
Fig. 1. Placement of voxels in the left STG, ACC (across 
midline), right STG, and left IFG shown in horizontal views. 
Center-of-mass for the voxel localization, given in MNI space 
x, y, z coordinates for the left IFG: −36.8, 18.9, 11.9, left STG: 
−48.3, −35.9, 6.02, right STG: 50.2, −34.2, 6.11, and for the ACC: 
0.389, 25.4, 33.9. The orange box illustrates the placement for a 
single representative subject. The red contours indicate 95%, and 
the green contours indicate 65% confidence regions for placement 
across the entire group (when mapped to a standard template). 
LSTG, left superior temporal gyrus; LIFG, left inferior frontal 
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spss-statistics-software). All multivariate analyses for Glx 
included a sample size of 77 patients and 77 controls, while 
GABA analyses included 76 patients and 77 controls. First, 
2 multivariate models were applied to the data, with Glx 
and GABA+ as dependent variables, respectively, to test for 
overall and regional differences between patients and controls. 
Participants were modeled as a random factor, while group 
(patients vs controls) and region (left and right STG, ACC, 
and IFG) were entered as fixed factors, and region as a re-
peated measure. Similar models were estimated for subgroups 
of patients using a median-split into high (AVH+, P3 score > 
2, n = 38) and low hallucinators (AVH-, P3 score < 2, n = 39) 
which resulted in 3 levels for the Group factor (AVH+, AVH-, 
and controls). Fisher’s LSD post hoc test was used to fol-
low-up significant interactions. Subsequently, 2 multivariate 
models with Glx and GABA+ as dependent variables were 
run for patients only in order to test the linear relationship 
between regional metabolites and severity of AVHs. In these 
models, Region was entered as a repeated fixed factor, and 
P3 AVH score was entered as a regressor variable, while par-
ticipants were modeled as a random factor. Post hoc testing 
in order to explore Region × AVHs interaction was done by 
splitting the multivariate regression models into lower-level 
models (one per region, with sample sizes: LSTG Glx = 76, 
GABA = 68; LIFG Glx = 37, GABA = 37; ACC Glx = 38, 
GABA = 37; RSTG Glx = 37, GABA = 32) while keeping 
the AVH variable as a regressor variable. The last analysis was 
thereafter repeated with the total negative symptom score, re-
placing the P3, as a regressor. In general, a simple model struc-
ture (scaled identity option) was chosen due to the relatively 
small sample size. Restricted log-likelihood test and Swartz’s 
Bayesian criterion showed that little was to gain in terms of 
model fit by choosing a more complex model structure.
Analyses were conducted to rule out the change of coil as 
a factor that could have biased the investigated relationship 
between AVH and Glx and GABA for the left STG. First, a 
chi-square test showed no difference between the AVH+ and 
AVH- groups in terms of how many patients in each group 
were tested with the 2 respective coils (P = .34). Second, there 
was no significant difference between the correlation coeffi-
cients of AVH against metabolites (Glx [P =  .74], GABA 
[P = .16]) for data collected with the 2 respective coils.
Results
Mean and SD for Glu, Gln, Glx, and GABA+ in patients 
and controls are seen in table 1.
Glx
A first analysis comparing patients and controls was 
nonsignificant for main-effect of Glx (F(1,142.58) = 1.3, 
P  =  .26), and interaction-effect of Group × Region 
source (F(3,305.5) = 0.88, P =  .45). The main-effect of 
Region was, however, significant (F(3,305.5) = 49.3, P < 
.001), and pairwise post hoc comparisons showed signifi-
cant differences between all 4 regions (all P < .001), with 
regional Glx levels ranging from highest to lowest in fol-
lowing order: right STG, ACC, left IFG, left STG. When 
dividing the patients into AVH+ vs AVH- sub-groups, 
the main-effect of Region (F(3,298.49) = 51.27, P < .001) 
remained significant, and main-effect of Group (F(2, 
177.87) = 0.79, P = .46) nonsignificant, but now a signif-
icant interaction-effect of Group × Region was observed 
(F(6, 295.24) = 2.22, P = .04; see figure 2).
Post hoc comparisons showed that the interaction was 
driven by higher Glx levels in the AVH+ vs AVH- sub-
group in the left STG (P  =  .04), while the reverse was 
true for the ACC, with lower Glx levels in the AVH+ sub-
group compared to the AVH- sub-group (P = .03). There 
was also a nonsignificant trend for the AVH- sub-group to 
show higher Glx levels compared to the controls (P = .07).
The next set of analyses involved patients only and 
assessed the linear relationship between AVH and Glx. 
Again, there was a significant main-effect of Region, 
(F(3,171.78) = 20.56, P < .001), while the main-effect of 
AVH was nonsignificant (F(1,125.4) = 0.05, P = .83, re-
spectively). However, the interaction of Region and AVH 
severity was significant (F(3,170.1) = 4.38, P = .005). Post 
hoc analyses showed that the interaction was driven by 
a marginally significant positive correlation between Glx 
levels in the left STG and P3 score (P = .054, B = 0.46), 
and a significant negative correlation between Glx and 
the P3 score in the ACC (P = .04, B = 0.56; see figure 3). 
AVHs were not significantly correlated with Glx levels in 
the right STG (P  =  .93, B  =  −0.14) or in the left IFG 
(P = .79, B = −0.06).
Total negative symptom score was not found related 
to Glx.
GABA+
In the analysis comparing overall GABA+ levels for pa-
tients vs controls, only the main-effect of Region was sig-
nificant (F(3,280.1) = 7.79, P < .001). Post hoc analyses 
showed a significant difference (P < .05) between all re-
gions (ranged from highest to lowest levels: LIFG, LSTG, 
RSTG, and ACC) except for right STG compared with 
left STG and ACC. When splitting the patients into the 
AVH+ and AVH- sub-groups, there were still no signif-
icant Group or interaction-effects (figure 2). The main-
effect of Region remained significant (F(3,276.31) = 7.57, 
P < .001). The model assessing the linear relationship be-
tween AVHs and GABA+ did not come out significant 
for any comparison. Lower-level models conducted for 
each region separately did not change these results.
A trend of a negative linear relationship between total 
negative symptom score and GABA+ was found (F(1, 
84.99) = 3.5, P = .065) across regions.
Discussion
The current study investigated the neurochemical under-











within selected brain regions, and Glu-Glu and GABA-
GABA imbalances between regions previously associated 
with hyper- and hypo-activity during AVH experience. 
No overall differences between patients and controls 
were found. However, significant differences were found 
between patient groups, where AVH+ patients showed 
lower ACC and higher left STG Glx levels relative to the 
AVH- group (figure  2). The control group showed Glx 
levels which were in between those of the AVH+ and 
AVH- patients. These findings were confirmed by corre-
lation analysis, where an interaction was found between 
brain region and AVH severity. The interaction was 
driven by a negative relationship between ACC Glx and 
the AVH score, whereas a positive relationship was shown 
between left STG Glx and the AVH score (figure 3).
Glu Levels: STG and IFG Voxels
As hypothesized, Glx in the left STG was positively as-
sociated with AVH severity. Although the correlation 
was marginally significant, previous findings by Hugdahl 
et al28 and Curic-Blake et al29 suggest that an a priori hy-
pothesis could be formulated regarding the direction of 
the correlation. Therefore, a one-sided test could have 
been argued for and would, in this case, shown a signifi-
cant effect.
In this sense, the present results extend the findings by 
Hugdahl et al28 on a larger sample. The results are also 
in line with previous fMRI findings showing increased 
activation in the left STG during AVH experiences.1,4 
This is not surprising when seen in the light of func-
tional MRS studies that show significant increase in Glx 
levels during stimulus processing and task execution.38,39 
In this sense, left STG Glx levels might cause neuronal 
hyper-excitation that initiate the perceptual experience of 
“hearing a voice.” In spite of a positive association be-
tween left STG Glx and AVH severity, the patients did 
not show overall higher Glx levels as compared to con-
trols. One could, therefore, speculate that the increased 
neuronal activity associated with AVHs elevates Glx to 
“normal levels” corresponding to that of healthy individ-
uals. This is further supported by the finding of lowest 
Glx levels in AVH- group, also lower than the controls. 
It should, however, be noted that neuronal activity was 
not measured. We can therefore not rule out that Glx 
would rather be associated with hypo-activity due to neu-
ronal loss as a consequence of neurotoxic effects of Glx.40 
However, since AVHs have previously been associated 
with left STG hyperactivity, we find the results of a posi-
tive relationship between Glx and AVHs to be unlikely if  
Glx would cause hypo-activity.
Interestingly, the positive association between Glx and 
AVH experiences was restricted to the left STG, suggesting 
a laterality effect implicating more the left than the right 
hemisphere. This result is in line with several fMRI meta-
analyses1,4 showing left, but not right, STG activations in 
patients with AVHs. Since the left hemisphere is the dom-
inant hemisphere for language processing41–43 and since 
AVH are typically experienced as “voices,” 31 an increase 
in Glx levels in left STG only is a feasible finding.
There was a lack of significant findings for the 
left IFG, which contradicts 2 previous MRS studies: 
Hugdahl et al28 and Ćurčić-Blake et al29 both found lower 
Glx levels in patients relative to controls, and higher Glx 
levels in hallucinating relative to non-hallucinating pa-
tients. Several methodological differences between the 
studies could explain the discrepancies in results, such 
as voxel placement (more medial and anterior in former 
studies), or sample characteristics such as lower P3 scores 
in Hugdahl et al, and AVH assessed as a trait measure in 
Fig. 2. Glutamate and GABA concentration levels are shown on the y-axes for healthy controls, low-hallucinating patients (AVH-
), and high-hallucinating patients (AVH+) in the 4 brain regions. Error bars indicate standard error. * indicates significant post hoc 
comparisons at P < .05, conducted to explore the significant interaction of Group and Region. STG, superior temporal gyrus; IFG, 
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Ćurčić-Blake et al. as opposed to a state measure in the 
current study.
Glx Levels: ACC Voxel
As hypothesized, ACC Glx levels were found to be 
negatively correlated with AVH. This could be related 
to neuronal hypo-activity and reduced executive and 
cognitive control functions that has been observed in 
hallucinating schizophrenia patients.6,44–47 A  possible 
interpretation is that patients with low Glx levels lack 
the cognitive resources necessary to inhibit the “voices” 
originating from the left STG, due to top-down hypo- 
and bottom-up hyper-excitation cf.10,11 Interestingly, no 
association was found between total negative symptom 
score and Glx levels in ACC, nor in any of the other re-
gions, highlighting the specificity of AVHs symptoms in 
predicting Glx concentrations.
The finding of no overall ACC Glx level difference be-
tween patients and controls adds to previous inconsistent 
Fig. 3. Graphs illustrating relations between glutamate or GABA levels (y-axis) and AVHs (x-axis) in left STG and ACC. Note that fixed 











findings, with some studies showing higher Glx levels 
in patients relative to controls,48,49 other showing lower 
levels,50,51 and others again reporting no difference.52–54 
However, when taking AVH into account, a significant 
group-effect appeared, driven by differences between the 
2 patient sub-groups (AVH+ and AVH-). There was also 
a trend towards higher Glx levels in the AVH- group com-
pared to the control group.
Thus, as for both the ACC and left STG regions, 
the healthy controls showed Glx levels in between the 
levels for the AVH+ and AVH- sub-groups. The ACC 
results, therefore, suggest that one reason for incon-
sistencies in previous studies when comparing schiz-
ophrenia patients and controls could, at least partly, 
be due to inter-individual heterogeneity in symptom 
severity, in particular, severity of  AVHs. AVH should, 
therefore, be reported or controlled for in future MRS 
studies.
GABA+ Levels: All Voxels
GABA+ levels were not found to differ between patients 
and controls, nor were GABA+ levels associated with 
AVHs. Previous GABA MRS studies have shown incon-
sistent results, in spite of consistent postmortem findings 
of reduced GAD67 mRNA production.25 The current 
study showed that even when inter-individual and inter-
regional differences were taken into account, the meas-
urements failed to show GABAergic alterations in the 
patients. de Jonge et al22 suggested that other subclasses 
of GABAergic neurons might compensate for the reduced 
GABA production in parvalbumin-neurons, or could be 
stimulated by increased glutamergic activity. This would 
be a plausible explanation for the left STG findings where 
Glx was elevated in AVH+ patients.
Intra-Regional vs Inter-Regional E/I-Imbalances
The current study investigated the underlying neuro-
chemistry in terms of the E/I- imbalance model for AVHs. 
While the results could not unambiguously confirm intra-
regional Glu-GABA imbalances due to the lack of signifi-
cant GABA findings, we found an inter-regional Glu-Glu 
imbalance associated with AVH severity. We thus pro-
pose a revised and extended E/I-imbalance model where 
Glu-Glu imbalance between brain regions may be more 
relevant than Glu-GABA imbalance within regions, for 
the understanding of the underlying neurochemistry 
of AVHs.
The suggested region-specificity regarding the relation 
between Glx and AVH give rise to questions of underlying 
mechanisms. It is increasingly accepted that NMDA receptor 
deficiency should result in elevated Glu and reduced GABA 
production in schizophrenia patients.24,55,56 If NMDA receptor 
deficiency, as eg, indicated by compensatory up-regulation 
of NMDA receptor subunits,57,58 underpin the results of the 
current study, they are likely to be region-specific, and Glx 
alterations seen in other regions secondary. One possibility 
is that dysfunction of NMDA-receptors in the left STG58,59 
causes neuronal hyperactivity and elevated Glx levels, leading 
to the perceptual experience of “hearing a voice.” In a non-
dysfunctional brain, the ACC would be similarly activated 
to suppress or inhibit the “voices” to enter awareness. In the 
hallucinating brain, this top-down regulation might be upset 
because of low ACC Glx levels, together with, or as a conse-
quence of, “strong” bottom-up perceptual impulses, resulting 
in AVH. It should, however, be remembered that MRS do 
not measure NMDA- receptor function per se, and therefore 
further studies applying, eg, PET-MR, may be instrumental 
in disentangle cause and effect with regard to the underlying 
neurochemistry of AVH. Another limitation of the current 
study is that different numbers of patients were assessed in the 
2 regions, and therefore, it remains undetermined whether the 
regional alterations co-exist in the same patients. With these 
limitations in mind, the findings may nevertheless point in 
new directions for the development of symptom-specific tar-
gets for pharmacological treatment interventions.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin online.
Figure S1: Examples of PRESS and MEGA-PRESS 
spectra from one patient and one control subject in each 
of the four regions. Abbreviations: STG=superior tem-
poral gyrus, IFG=inferior frontal gyrus, ACC=anterior 
cingulate cortex. All spectra were subjected to quality 
control, before included in data analysis. A  local algo-
rithm assigned a quality score to each spectra, consid-
ering the following factors: spectral linewidth (FWHM), 
signal-to-noise ratio (SNR) and CRLB %SD of key me-
tabolites in the spectrum, the magnitude of aberrant fea-
tures in the individual metabolite spectrum relative to the 
group mean, and the magnitude of features in the resid-
uals after fitting. This quality score does not impose strict 
rejection criteria (which in some instances could risk 
introducing systematic biases 60), but rather flags aspects 
of spectra of possible concern to guide visual inspection, 
after which spectra deemed to be of insufficient quality 
for meaningful assessment were rejected.
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